Prometrium Medicaid Coverage by State Tier: What Every Woman Needs to Know in 2026

What Is Prometrium and Why Do Women Use It

Prometrium is a brand name for oral micronized progesterone, a bioidentical hormone that matches the molecular structure of the progesterone your ovaries produce. It is distinct from synthetic progestins such as medroxyprogesterone acetate (MPA), and that distinction matters clinically.

Approved Uses

The FDA-approved indications for Prometrium are:

• Endometrial protection in postmenopausal women taking estrogen therapy (200 mg nightly for 12 days per 28-day cycle, or 100 mg nightly continuously)
• Secondary amenorrhea (400 mg nightly for 10 days)

Common Off-Label Uses in Women

Clinicians also prescribe micronized progesterone off-label for a wide range of women's-health conditions, including:

• Perimenopause symptom management (sleep, mood, hot flashes)
• Luteal-phase support in natural cycles and IVF
• Progesterone supplementation in early pregnancy after recurrent loss
• Corpus luteum deficiency
• PCOS-related cycle irregularity when hormonal contraception is not desired
• Premenstrual dysphoric disorder (PMDD)

The ACOG Clinical Practice Bulletin on Menopause notes that micronized progesterone has a more favorable side-effect profile compared with synthetic progestins for many women, particularly regarding breast tenderness and lipid effects.

The framework below organizes Medicaid access by three tiers of state behavior. Most women trying to access Prometrium will fall into one of these categories, and knowing your tier tells you exactly what paperwork you may face.

How Medicaid Drug Coverage Works: Tiers Explained

Medicaid is not a single national drug plan. Each state runs its own Preferred Drug List (PDL), and each PDL places drugs into tiers that determine cost-share, prior authorization (PA), and step-therapy requirements.

Tier Definitions Relevant to Prometrium

| Tier Label | What It Means for You | |---|---| | Preferred Generic | Lowest or zero copay; no PA required; filled at any Medicaid pharmacy | | Non-Preferred Generic | Low copay but PA may be required if a preferred product is available | | Preferred Brand | Brand covered without PA; higher copay than generic | | Non-Preferred Brand | PA required; step-therapy through generic first is common | | Excluded / Not Listed | Drug not covered; must use alternative or request exception |

Because a 2007 FDA approval brought generic micronized progesterone to market, nearly every state Medicaid program now places the generic in Tier 1 (preferred generic) and places brand-name Prometrium in a non-preferred or excluded tier. This means most women will access micronized progesterone without PA, but will receive a generic, not the AbbVie brand.

Prometrium Medicaid Coverage by State Tier (2026 Snapshot)

State Medicaid PDLs are updated quarterly. The information below reflects published PDL data as of early 2026. Always verify with your state Medicaid pharmacy help desk or your pharmacist before assuming coverage.

Tier 1 States: Generic Preferred, No PA Required

The majority of states place generic micronized progesterone 100 mg and 200 mg on their preferred drug list with no prior authorization. In these states, your copay is typically $0 to $4 per month for Medicaid beneficiaries.

States consistently in this category include California (Medi-Cal), New York (NYMC), Texas (STAR/CHIP), Florida Medicaid, Illinois, Pennsylvania, Ohio, Michigan, Georgia, North Carolina, and most of the remaining states. Generic micronized progesterone is so widely preferred that the practical question is not whether it is covered but whether your specific diagnosis code will satisfy the claim.

What to bring to the pharmacy: Your Medicaid ID, a prescription that lists "micronized progesterone" (not just "Prometrium") so the pharmacist can dispense the generic without calling your provider.

Tier 2 States: PA Required for Some Indications

A smaller group of states covers micronized progesterone broadly but requires prior authorization when the diagnosis code is an off-label use (for example, PCOS or luteal support rather than secondary amenorrhea or endometrial protection).

States that have historically required indication-based PA include certain managed-care plans within Texas, Indiana, and Louisiana. Requirements change frequently. CMS publishes aggregate Medicaid drug spending data but not real-time PDL tier data; your state Medicaid website is the authoritative source.

What helps with PA: A letter from your provider citing the diagnosis (ICD-10 code N91.1 for secondary amenorrhea, N95.1 for menopausal symptoms, or Z31.69 for infertility workup), the specific dose, and the duration of treatment. Many PA requests for micronized progesterone are approved within 48 to 72 hours.

Tier 3 States: Brand Prometrium Restricted or Excluded

Brand-name Prometrium (AbbVie) is non-preferred or excluded in the large majority of state Medicaid programs because the generic is bioequivalent and priced far lower. If your provider writes for brand-name only (with "dispense as written"), Medicaid will likely deny the claim or require a medical necessity exception demonstrating that you have a documented intolerance to the generic formulation (most commonly, sensitivity to peanut oil, which is present in the brand but also in most generics).

Peanut oil note: Both brand Prometrium and most generic micronized progesterone capsules contain peanut oil as an excipient. The FDA label carries a warning for patients with peanut allergy. If you have a documented peanut allergy, you may qualify for a medical necessity exception to access a compounded peanut-oil-free formulation, though compounded drugs carry their own coverage complexities under Medicaid.

Sex-Specific Pharmacology: How Your Hormonal Status Changes Everything

Micronized progesterone behaves differently depending on your reproductive stage. This is not a minor footnote; it changes dosing, timing, and what to watch for.

Reproductive Years and the Menstrual Cycle

During your reproductive years, endogenous progesterone surges after ovulation, reaching peak levels of 15 to 25 ng/mL in the mid-luteal phase. Oral micronized progesterone is metabolized by the liver into neurosteroid metabolites including allopregnanolone, which acts on GABA-A receptors. This explains why some women feel sedated or have vivid dreams after taking it orally, especially at the 200 mg dose. Taking it at bedtime is standard practice precisely because of this effect.

Progesterone absorption varies with your cycle phase. Food increases bioavailability by approximately 60%, according to pharmacokinetic data in the Prometrium prescribing information. Taking it with a small snack at bedtime maximizes absorption and softens the sedative hit.

Perimenopause

During perimenopause, progesterone levels fall before estrogen does. This estrogen-progesterone imbalance is a major driver of irregular cycles, poor sleep, and worsening PMS-like symptoms. Micronized progesterone at 100 mg nightly has been studied in this context. The PEPI trial (Postmenopausal Estrogen/Progestin Interventions), which enrolled 875 postmenopausal women, found that micronized progesterone combined with estrogen produced a more favorable HDL-cholesterol profile than MPA-based regimens. While the PEPI trial studied postmenopausal women, the lipid-friendliness of micronized progesterone is cited in perimenopausal prescribing practice.

Postmenopause

In postmenopause, Prometrium's FDA-approved indication is endometrial protection. Women taking systemic estrogen therapy need a progestogen to prevent endometrial hyperplasia. The Menopause Society (formerly NAMS) 2022 Hormone Therapy Position Statement states that micronized progesterone is an acceptable progestogen for endometrial protection and may be preferred by some women because of its favorable effect on sleep and mood compared with synthetic progestins.

Pregnancy and Lactation Safety: Required Reading

If you could become pregnant, read this section before filling your prescription.

Pregnancy

Micronized progesterone carries FDA Pregnancy Category B for luteal-phase support and early pregnancy supplementation. Animal reproduction studies have not demonstrated fetal risk, but adequate and well-controlled studies in pregnant women are limited.

Prometrium is prescribed off-label in early pregnancy for:

• Luteal support in assisted reproduction
• Threatened miscarriage in women with documented low progesterone
• Recurrent pregnancy loss (RPL)

The PROMISE trial (published in NEJM, 2015) enrolled 836 women with unexplained recurrent miscarriage and found that vaginal micronized progesterone did not significantly improve live birth rates compared with placebo (65.8% vs 63.3%, p=0.38). However, subsequent trials and meta-analyses have found benefit in subgroups, particularly women with early pregnancy bleeding. The PRISM trial (Lancet, 2019) found that vaginal progesterone 400 mg twice daily significantly improved live birth rates in women with first-trimester bleeding and a history of miscarriage (65% vs 60%, p=0.007).

Important: Oral Prometrium capsules are not the same delivery route studied in PROMISE or PRISM. Vaginal progesterone achieves higher uterine concentrations. If your provider prescribes Prometrium for pregnancy support, clarify whether oral or vaginal use is intended. Some providers prescribe the capsule for vaginal insertion off-label.

Prometrium is NOT a contraceptive. Do not use it in place of birth control. If you are using it for non-pregnancy indications and do not want to become pregnant, continue your existing contraception.

Lactation

Progesterone transfers into breast milk in small amounts. LactMed (NIH) notes that progesterone levels in milk are low and that infant exposure through breast milk is unlikely to cause harm. However, exogenous progesterone may theoretically affect milk supply in some women, because progesterone withdrawal after delivery is part of the trigger for lactogenesis. Starting micronized progesterone while breastfeeding a newborn is generally deferred until milk supply is established, typically after the first 4 to 6 weeks postpartum. Discuss timing with your provider.

Who This Is Right For and Who Should Use Caution

Good Candidates

• Postmenopausal women using systemic estrogen who need endometrial protection
• Perimenopausal women with intact uteri using estrogen therapy
• Women undergoing IVF or frozen embryo transfer requiring luteal support
• Women with secondary amenorrhea seeking a cycle trigger
• Women with PCOS who prefer a non-contraceptive progesterone option to induce withdrawal bleeds

Use With Caution or Discuss Alternatives

• Peanut allergy: Both brand and most generic capsules contain peanut oil. This is a contraindication. A compounded peanut-oil-free formulation may be an option, though cost and insurance coverage differ.
• Liver disease: Progesterone is hepatically metabolized. Severe hepatic impairment is a contraindication listed in the FDA label.
• History of or current thromboembolic disease: Synthetic progestins (not micronized progesterone) carry a higher VTE signal, but any progestogen in a high-risk woman warrants discussion with her clinician.
• Unexplained vaginal bleeding: Requires workup before starting therapy.
• Women who drive or operate heavy machinery at night: The sedative metabolites of oral progesterone can impair next-morning alertness at higher doses. Vaginal route largely bypasses this effect.

How to Get Prometrium Cheaper: Four Concrete Strategies

Medicaid is one pathway, but not every woman qualifies. Here are four evidence-based strategies to reduce cost.

1. Switch to Generic Micronized Progesterone

The generic is FDA-bioequivalent. At most retail pharmacies, a 30-day supply of generic micronized progesterone 100 mg costs $25 to $55 without insurance. GoodRx prices in 2025 ranged from approximately $18 to $45 depending on pharmacy and dose.

2. Use GoodRx, RxSaver, or SingleCare

These free discount cards apply at most major chains and many independents. They cannot be combined with Medicaid, but for uninsured or commercially insured women with high cost-share, they often beat the insurance price. Always compare the discount card price against your plan's copay before paying.

3. AbbVie Patient Assistance Program (for Brand Prometrium)

AbbVie offers the myAbbVie Assist program for patients who meet income criteria and are uninsured or underinsured. Applications require income documentation and a provider signature. Processing takes 2 to 4 weeks.

4. Compounding Pharmacy (Last Resort for Unique Situations)

Compounded micronized progesterone is not FDA-approved and is not covered by Medicaid. It is relevant only when a woman has a documented intolerance to commercial excipients (such as peanut oil allergy) or needs a non-standard dose. Compounded products lack the bioequivalence testing of FDA-approved generics, and ACOG recommends using FDA-approved formulations whenever available.

HSA and FSA Eligibility for Prometrium

Yes. Prometrium and generic micronized progesterone are eligible for payment through a Health Savings Account (HSA) or Flexible Spending Account (FSA) when dispensed with a valid prescription. The IRS defines eligible medical expenses to include prescription drugs, and progesterone is a prescription drug in all U.S. States.

Practical steps:

1. Obtain a valid prescription from your provider.
2. Pay at the pharmacy using your HSA or FSA debit card, or pay out of pocket and submit the receipt for reimbursement.
3. Keep the pharmacy receipt showing the drug name, date, and amount paid. Most HSA/FSA administrators accept this without further documentation.

Over-the-counter progesterone creams are not equivalent to oral micronized progesterone and are not covered as prescription drugs unless specifically prescribed by a provider and dispensed by a pharmacy.

Navigating Prior Authorization for Prometrium on Medicaid

Prior authorization denials are frustrating but often reversible. Here is a step-by-step process.

Step 1: Ask Why the Claim Was Denied

Request the denial reason in writing. Common reasons include: brand requested when generic preferred, diagnosis code not matching an approved indication, or missing prescriber NPI.

Step 2: Your Provider Submits the PA Form

Every state Medicaid program has a downloadable PA form or an electronic PA portal. Your provider's office can usually submit within one business day. Include:

• ICD-10 diagnosis code
• Rationale for brand if requesting brand (e.g., documented peanut allergy with generic intolerance)
• Duration and dose requested
• Relevant labs or clinical notes

Step 3: Appeal if Denied Again

If the PA is denied, you have the right to a formal appeal and, in most states, an expedited appeal for urgent clinical situations. A prescriber letter explaining medical necessity carries significant weight. The CMS Medicaid managed care regulations require states to resolve standard appeals within 30 days and expedited appeals within 72 hours.

Step 4: Request a State Fair Hearing

If your appeal is denied and you believe the denial was incorrect, you may request a state fair hearing. This is rarely needed for micronized progesterone given its wide Medicaid coverage, but it is your legal right.

Evidence Gap: What We Don't Know Yet

Women have been historically under-represented in pharmacokinetic studies. Here is what remains extrapolated rather than directly proven:

• PK data by BMI: Absorption and clearance of oral micronized progesterone in women with obesity (BMI above 35) has not been well characterized in dedicated trials. Dose adjustments are not currently evidence-based.
• Race and ethnicity: CYP3A4 activity, which drives progesterone metabolism, varies across populations, but no large trials have examined whether dose optimization should differ by ancestry.
• Perimenopausal dosing: Most efficacy data comes from postmenopausal women. Perimenopausal dosing is largely extrapolated, as stated in The Menopause Society's 2022 position statement.

Acknowledging these gaps is not a reason to avoid the drug. It is a reason to monitor your response and report unexpected symptoms to your provider.

Clinician Perspective

As WomanRx reviewer Dr. Rachel Goldberg, MD, notes: "Micronized progesterone is one of the most commonly prescribed hormones in women's health, yet many of my patients are surprised to learn that their state Medicaid plan covers the generic without any prior authorization. The first question I ask when a patient says she can't afford her progesterone is whether she's tried the generic at a Medicaid-preferred pharmacy. That single step resolves the access problem for most women."